Please use this identifier to cite or link to this item: https://www.arca.fiocruz.br/handle/icict/65613

Type
Article
Copyright
Open access
Collections
Share

Statistics
Metadata
Show full item record

SOFOSBUVIR OFF-LABEL TREATMENT OF YELLOW FEVER PATIENTS DURING AN OUTBREAK IN BRAZIL, 2018, A COHORT STUDY.
Rezende, Izabela M et al. | Date Issued: 2024
Author
Rezende, Izabela M
Mendonça, Diogo Correa
Costa, Thais Alkifeles
Oliveria, Gabriela Fernanda Garcia de
Arruda, Matheus Soares
Gonçalves, Andreza Parreiras
Alves, Pedro Augusto
Silva, Carlos Eduardo Calzavara
Martins Filho, Olindo Assis
Carvalho, Andréa Teixeira de
Bonjardim, Claudio Antonio
Monath, Thomas P
LaBeaud, A Desiree
Drumond, Betânia P
Xavier, Marcelo Antônio Pascoal
Pereira, Leonardo S
Ramalho, Dario Brock
Affilliation
Department of Pediatrics, Division of Infectious Diseases. Stanford University School of Medicine. Stanford, CA, USA/Laboratory of Viruses. Microbiology Department. Biological Sciences Institute. Universidade Federal de Minas Gerais. Belo Horizonte, MG, Brazil.
Centre for Virus Research. Medical Research Council/University of Glasgow. Glasgow, United Kingdom.
Laboratory of Viruses. Microbiology Department. Biological Sciences Institute. Universidade Federal de Minas Gerais. Belo Horizonte, MG, Brazil.
Laboratory of Viruses. Microbiology Department. Biological Sciences Institute. Universidade Federal de Minas Gerais. Belo Horizonte, MG, Brazil.
Laboratory of Viruses. Microbiology Department. Biological Sciences Institute. Universidade Federal de Minas Gerais. Belo Horizonte, MG, Brazil.
Immunology of Viral Diseases. René Rachou Institute. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil.
Immunology of Viral Diseases. René Rachou Institute. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil.
Cellular and Molecular Immunology. René Rachou Institute. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil
Integrated Group of Biomarkers Research. René Rachou Institute. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil.
Integrated Group of Biomarkers Research. René Rachou Institute. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil.
Laboratory of Viruses. Microbiology Department. Biological Sciences Institute. Universidade Federal de Minas Gerais. Belo Horizonte, MG, Brazil.
Crozet BioPharma LLC. Lexington, MA, USA.
Department of Pediatrics, Division of Infectious Diseases. Stanford University School of Medicine. Stanford, CA, USA.
Laboratory of Viruses. Microbiology Department. Biological Sciences Institute. Universidade Federal de Minas Gerais. Belo Horizonte, MG, Brazil.
Immunology of Viral Diseases. René Rachou Institute. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil.
Eduardo de Menezes Hospital. Belo Horizonte, MG, Brazil.
Eduardo de Menezes Hospital. Belo Horizonte, MG, Brazil.
Abstract
We enrolled 21 patients with laboratory-confirmed yellow fever (YF), hospitalized at Eduardo de Menezes Hospital, Brazil, to be treated with sofosbuvir, a drug approved for hepatitis C. Given the absence of specific YF antiviral treatments, the off-label nonrandomized sofosbuvir treatment aimed to address high disease severity and the risk of fatal outcomes. Patients received a daily dose of 400 mg sofosbuvir from 4 to 10 days post-symptom onset. YF viral load (VL) comparisons were made between treated and nontreated patients who either survived or died. The genomic VL for the treated group steadily decreased after day 7 post-symptom onset, suggesting that sofosbuvir might reduce YF VL. This study underscores the urgent need for YF antiviral therapies, advocating for randomized clinical trials to further explore sofosbuvir's role in YF treatment.
Keywords
antiviral
genomic viral load
sofosbuvir
yellow fever
yellow fever virus
 
Publisher
Oxford University Press on behalf of the Infectious Diseases Society of America
Citation
REZENDE, Izabela M et al. Sofosbuvir off-label treatment of yellow fever patients during an outbreak in Brazil, 2018, a cohort study. Open Forum Infect Dis, v. 9, n. 6, 132, 2024. doi: 10.1093/ofid/ofae312.
ISSN
2328-8957